Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG

Circulation Journal

Volumn 73, Issue 7, 2009, Pages 1210-1218

  Niwano, Shinichi ^a   Sasaki, Takeshi ^a   Kurokawa, Sayaka ^a   Kiryu, Michiro ^a   Fukaya, Hidehira ^a   Hatakeyama, Yuko ^a   Niwano, Hiroe ^a   Fujiki, Akira ^b   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Antiarrhythmic agent; Atrial fibrillation; Fibrillation wave; Spectral analysis

Indexed keywords

BEPRIDIL; PILSICAINIDE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BODY SURFACE; CARDIOVERSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; ELECTROCARDIOGRAPHY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; SPIKE WAVE; TREATMENT DURATION;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BEPRIDIL; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPECTRUM ANALYSIS; TREATMENT OUTCOME;

EID: 68149180565     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-1139     Document Type: Article

References (29)

1. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666. (Pubitemid 28402090)
2. Shah DC, Haïssaguerre M, Jaïs P. Catheter ablation of pulmonary vein foci for atrial fibrillation. Thorac Cardiovasc Surg 1999; 47: 352-356.
3. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-521. (Pubitemid 27056221)
4. Katoh T, Ohara T, Ogawa S, Kodama I, committee members of the Guideline for Drug Treatment of Arrhythmias (JCS 2004). Multicenter survey on the validity of the CD-ROM guideline for antiarrhythmic drug therapy produced by the Japanese Circulation Society and the Japanese Society on Electrocardiology: Preliminary report of the survey of the Japanese guideline for Arrhythmia Management By Individual Therapy (J-GAMBIT). Circ J 2005; 69: 1357-1360. (Pubitemid 41560815)
5. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation: Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994; 90: 2032-2040. (Pubitemid 24320956)
6. Fujiki A, Sakabe M, Nishida K, Sugao M, Tsuneda T, Iwamoto J, et al. Drug-induced changes in fibrillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine. Circ J 2004; 68: 1139-1145.
7. Sasaki T, Niwano S, Sasaki S, Imaki R, Yuge M, Hirasawa S, et al. Long-term follow-up of changes in fibrillation waves in patients with persistent atrial fibrillation: Spectral analysis of surface ECG. Circ J 2006; 70: 169-173. (Pubitemid 43170127)
8. Fujiki A, Nagasawa H, Sakabe M, Sakurai K, Nishida K, Mizumaki K, et al. Spectral characteristics of human atrial fibrillation waves of the right atrial free wall with respect to the duration of atrial fibrillation and effect of class I antiarrhythmic drugs. Jpn Circ J 2000; 65: 1047-1051. (Pubitemid 33126516)
9. Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K; Kanagawa Arrhythmia Task Force investigators. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study. Am Heart J 2000; 140: e13.
10. Atarashi H, Inoue H, Hiejima K, Hayakawa H. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation): The PSTAF Investigators. Am J Cardiol 1996; 78: 694-697.
11. Fujiki A, Tsuneda T, Sakabe M, Nakagawa K, Mizumaki K, Hirai T, et al. Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. Circ J 2004; 68: 834-839. (Pubitemid 39243804)
12. Nakazato Y, Yasuda M, Sasaki A, Iida Y, Kawano Y, Nakazato K, et al. Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-48.
13. Yoshida T, Niwano S, Inuo K, Saito J, Kojima J, Ikeda-Murakami K, et al. Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 2003; 26: 314-317. (Pubitemid 36399163)
14. Niwano S, Fukaya H, Sasaki T, Hatakeyama Y, Fujiki A, Izumi T. Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: Spectral analysis of fibrillation waves in the Holter monitoring. Europace 2007; 9: 1209-1215. (Pubitemid 351773253)
15. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, et al. Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol 2004; 43: 178-182. (Pubitemid 38129674)
16. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
17. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 1997; 96: 4027-4035. (Pubitemid 27506062)
18. Fujiki A, Sakamoto T, Iwamoto J, Nishida K, Nagasawa H, Mizumaki K, et al. Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. Circ J 2006; 70: 1138-1141. (Pubitemid 44386993)
19. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S, et al. Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 2007; 71: 1250-1257. (Pubitemid 47195342)
20. Imai S, Saito F, Takase H, Enomoto M, Aoyama H, Yamaji S, et al. Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. Circ J 2008; 72: 709-715. (Pubitemid 351716674)
21. Niwano S, Ortiz J, Abe H, Gonzalez X, Rudy Y, Waldo AL. Characterization of the excitable gap in a functionally determined reentrant circuit: Studies in the sterile pericarditis model of atrial flutter. Circculation 1994; 90: 1997-2014. (Pubitemid 24320953)
22. + channel blockade. Circ J 2007; 71(Suppl): A-26-A-31. (Pubitemid 46997999)
23. Yamazaki M, Honjo H, Nakagawa H, Ishiguro YS, Okuno Y, Amino M, et al. Mechanisms of destabilization and early termination of spiral wave reentry in the ventricle by class III antiarrhythmic agents, nifekalant. Am J Physiol Heart Circ Physiol 2007; 292: H539-(Pubitemid 46105218)
24. H548.
25. Nishida K, Fujiki A, Sakamoto T, Iwamoto J, Mizumaki K, Hashimoto N, et al. Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tachycardia. J Cardiovasc Electrophysiol 2007; 18: 1-8. (Pubitemid 46934525)
26. Fukaya H, Niwano S, Satoh D, Masaki Y, Niwano H, Kojima J, et al. Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model. Circ J 2008; 72: 318-326.
27. Sato D, Niwano S, Imaki R, Masaki Y, Sasaki S, Yuge M, et al. Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model. Circ J 2006; 70: 206-213. (Pubitemid 43170134)
28. Shinagawa K, Mitamura H, Takeshita A, Sato T, Kanki H, Takatsuki S. Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: Direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol 2000; 35: 246-253. (Pubitemid 30061287)
29. Niwano S, Wakisaka Y, Kojima J, Yumoto Y, Inuo K, Hara H, et al. Monitoring the progression of the atrial electrical remodeling in patients with paroxysmal atrial fibrillation: Analysis of the f-f interval during atrial fibrillation in the ambulatory ECG monitoring. Circ J 2003; 67: 133-138. (Pubitemid 36205653)